Wockhardt Limited

WOCKPHARMA

INE049B01025

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:43:50 2024-06-06 EDT			5-day change	1st Jan Change
545.4 ^INR	+4.86%		-3.08%	+28.53%

05-29	Wockhardt Narrows Consolidated Net Loss in Fiscal Q4	MT
05-28	Wockhardt Limited Appoints Ahmad Javed as Additional (Independent) Director	CI

Wockhardt Limited Appoints Deepak Madnani as Chief Financial Officer

January 27, 2022 at 02:21 am

Wockhardt Limited announced board of directors of the company at its meeting held 27 January 2022, Mr. Deepak Madnani will be acting Chief Financial Officer of the Company with effective from 1st March 2022.

Latest news about Wockhardt Limited

Wockhardt Narrows Consolidated Net Loss in Fiscal Q4	05-29	MT
Wockhardt Limited Appoints Ahmad Javed as Additional (Independent) Director	05-28	CI
Wockhardt Limited Provides Zidebactam/Cefepime, WCK 5222 Update	05-28	CI
Wockhardt Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	05-28	CI
Wockhardt Limited Announces Cessation of Independent Directors	04-03	CI
Wockhardt Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-14	CI
Wockhardt Limited Announces Successful Completion of Pivotal Phase 3 Pneumonia Study of Its Macrolide Antibody Nafithromycin WCK 4873	12-11	CI
Wockhardt Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-14	CI
CARE Cuts Rating on Wockhardt's Working Capital to BB+; Outlook Negative	23-09-06	MT
Wockhardt Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-14	CI
Wockhardt Limited Announces Executive Changes	23-08-14	CI
CARE Keeps BBB- Rating on Wockhardt's Bank Financing	23-06-07	MT
Wockhardt Trims Consolidated Loss in Fiscal Q4	23-05-29	MT
Wockhardt Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-26	CI
INDIA STOCKS-Indian shares fall on rate-hike worries ahead of Fed, RBI minutes	23-02-22	RE
Wockhardt Widens Consolidated Net Profit in Fiscal Q3	23-02-14	MT
Wockhardt Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-13	CI
Wockhardt Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-04	CI
CARE Keeps Rating on Wockhardt's Long-term Bank Financing, Bonds; Outlook Stable	22-09-05	MT
Wockhardt Starts Global Phase 3 Clinical Study of Novel Antibiotic WCK 5222	22-08-16	MT
Wockhardt Announces Successful Initiation of Global Phase 3 Clinical Study of Its Novel Antibiotic WCK 5222	22-08-15	CI
Wockhardt Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-12	CI
Wockhardt Appoints New CFO	22-06-07	MT
Wockhardt Limited Announces Chief Financial Officer Changes	22-06-07	CI
Wockhardt Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2022	22-05-30	CI

Chart Wockhardt Limited

Duration

Period

More charts

Company Profile

Wockhardt Limited is a pharmaceutical and biotechnology company. The Company's businesses include manufacture and marketing of pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines. It manufactures a range of dosage forms, including sterile injectables and lyophilized products. The Company offers products in therapeutic areas of dermatology, cosmeceuticals, oncology, medical nutrition, osteoarthritis, pain management, nephrology, cough therapy and diabetology. The Companyâs products across India includes Citawok, Citawok Forte, Citawok Plus, CONSEGNA 30/70 U-200 CART, CONSEGNA R U-200 CART, DARBOTIN PFS, DECDAN, DECDAN B, DECDAN B Injection, DECDAN LITE CREAM, Emrok, Emrok O, Erliso, FOSCHEK-S, Gabawok NT, GLARITUS CART, GLARITUS DISPO, Glimaday, INOGLA, Livatira, GLARITUS CART and VAL 450. It has manufacturing and research facilities in India, United States of America and the United Kingdom and a manufacturing facility in Ireland.

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
WOCKHARDT LIMITED	+28.53%	957M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+16.93%	42.79B
OTSUKA HOLDINGS CO., LTD.	+22.65%	22.81B
SANDOZ GROUP AG	+16.96%	15.04B
CIPLA LIMITED	+18.51%	14.49B
ZYDUS LIFESCIENCES LIMITED	+51.63%	12.65B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-11.69%	6.74B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.27%	5.47B